Your browser doesn't support javascript.
loading
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
Deleuran, Mette; Thaçi, Diamant; Beck, Lisa A; de Bruin-Weller, Marjolein; Blauvelt, Andrew; Forman, Seth; Bissonnette, Robert; Reich, Kristian; Soong, Weily; Hussain, Iftikhar; Foley, Peter; Hide, Michihiro; Bouaziz, Jean-David; Gelfand, Joel M; Sher, Lawrence; Schuttelaar, Marie L A; Wang, Chen; Chen, Zhen; Akinlade, Bolanle; Gadkari, Abhijit; Eckert, Laurent; Davis, John D; Rajadhyaksha, Manoj; Staudinger, Heribert; Graham, Neil M H; Pirozzi, Gianluca; Ardeleanu, Marius.
Affiliation
  • Deleuran M; Aarhus University Hospital, Aarhus, Denmark. Electronic address: mettdele@rm.dk.
  • Thaçi D; University of Lübeck, Lübeck, Germany.
  • Beck LA; University of Rochester Medical Center, Rochester, New York.
  • de Bruin-Weller M; University Medical Center Utrecht, Utrecht, The Netherlands.
  • Blauvelt A; Oregon Medical Research, Portland, Oregon.
  • Forman S; Forman Dermatology and Skin Cancer Institute, Tampa, Florida.
  • Bissonnette R; Innovaderm Research, Montreal, Canada.
  • Reich K; Center for Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Skinflammation Center, Hamburg, Germany; Dermatologikum Berlin, Berlin, Germany.
  • Soong W; Alabama Allergy & Asthma Center, Birmingham, Alabama.
  • Hussain I; Vital Prospects Clinical Research Institute, PC, Tulsa, Oklahoma.
  • Foley P; University of Melbourne, Skin & Cancer Foundation, Inc., Carlton, Australia.
  • Hide M; Hiroshima University, Hiroshima, Japan.
  • Bouaziz JD; Saint-Louis Hospital, Paris, France.
  • Gelfand JM; University of Pennsylvania, Philadelphia, Pennsylvania.
  • Sher L; Peninsula Research Associates, Rolling Hills Estates, California.
  • Schuttelaar MLA; University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Wang C; Regeneron Pharmaceuticals, Inc., Basking Ridge, New Jersey.
  • Chen Z; Regeneron Pharmaceuticals, Inc, Tarrytown, New York.
  • Akinlade B; Regeneron Pharmaceuticals, Inc, Tarrytown, New York.
  • Gadkari A; Regeneron Pharmaceuticals, Inc, Tarrytown, New York.
  • Eckert L; Sanofi, Chilly-Mazarin, France.
  • Davis JD; Regeneron Pharmaceuticals, Inc, Tarrytown, New York.
  • Rajadhyaksha M; Regeneron Pharmaceuticals, Inc, Tarrytown, New York.
  • Staudinger H; Sanofi, Bridgewater, New Jersey.
  • Graham NMH; Regeneron Pharmaceuticals, Inc, Tarrytown, New York.
  • Pirozzi G; Sanofi, Bridgewater, New Jersey.
  • Ardeleanu M; Regeneron Pharmaceuticals, Inc, Tarrytown, New York.
J Am Acad Dermatol ; 82(2): 377-388, 2020 Feb.
Article in En | MEDLINE | ID: mdl-31374300
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dermatitis, Atopic / Antibodies, Monoclonal, Humanized Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: J Am Acad Dermatol Year: 2020 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Dermatitis, Atopic / Antibodies, Monoclonal, Humanized Type of study: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: J Am Acad Dermatol Year: 2020 Type: Article